|
|
|
| Therapeutic Effect and Drug Safety of Safflower Yellow Intramural Injection in Patients with Myofascial Pain Syndrome |
| YANG Min, XIAO Mingzhong |
| Hubei Provincial Traditional Chinese Medical Hospital, Hubei Wuhan 430074, China |
|
|
|
|
Abstract Objective: To investigate the clinical effect of carthamin yellow body wall injection for myofascial pain syndrome, and to observe the safety of the drug. Methods: 80 patients with myofascial pain syndrome diagnosed in our hospital from July 2016 to June 2017 were selected. The data of 80 patients were analyzed. They were randomly divided into the control group and the observation group, 40 cases in each group. The observation group was given carthamin yellow which use body wall injection, while the control group was treated with dexamethasone sodium phosphate injection. The improvement of clinical symptoms in the two groups was compared with the visual analogue scale (VAS) to evaluate the degree of pain in the two groups of patients after 2, 4, 6 and 8 weeks, and the clinical results were compared before and after treatment in the group. Results: The ratio of clinical symptoms improvement in the observation group (82.5%) was significantly higher than that in the control group (67.5%). There was no significant difference in the VAS scores between the two groups before and after treatment (P>0.05). After 2, 4, 6 and 8 weeks of treatment, the VAS score of the observation group was significantly lower than that of the control group (P<0.05). There was no significant difference in blood routine, liver and kidney function before treatment and after treatment in the observation group (P>0.05). Conclusion: The clinical application of carthamin yellow body wall injection can obviously reduce the pain degree of the patients, and the curative effect is stable. The quality of life of patients is greatly improved, and almost of the patients have no obvious side effects, and the drug safety is worth widely popularizing in clinical practice.
|
|
|
|
|
|
[1] 庞杰,周张玖智,侯加卫,等.红花黄色素对APP/PS 1双转基因小鼠脑组织中胶质细胞活化及炎症因子释放的影响[J].中药药理与临床,2018(1):85~88.
[2] 秦劭晨,梁伟雄,温晓文,等.注射用羟基红花黄色素A治疗急性缺血性中风血瘀证疗效观察[J].中国实验方剂学杂志,2016,22(21):157~161.
[3] 曾成,王宁华.肌筋膜疼痛综合征的治疗进展[J].中国康复理论与实践,2014,20(3):245~249.
[4] 王热爱,彭易雨,景绘涛.中药塌渍疗法治疗肌筋膜疼痛综合征150例疗效观察[J].时珍国医国药,2015,26(6):1420~1421.
[5] Fan S, Lin N, Shan G, et.al. Safflower yellow for acute ischemic stroke: A systematic review of randomizedcontrolled trials[J]Complement Ther Med,2014,22(2):354~361.
[6] 李新伟,杜嘉,谭克平,等.浮针疗法配合肌肉能量技术治疗颈肩肌筋膜疼痛综合征疗效观察[J].中华中医药杂志,2017,32(2):875~877.
[7] 罗平,林鸿生.对以针刺拉伸手法为主的综合方法治疗肌筋膜疼痛综合征的疗效研究[J].成都体育学院学报,2013,39(8):75~79,85.
[8] 黄玲玲,傅缨,资晓飞,等.红花黄色素对人肝癌细胞凋亡及相关蛋白表达的影响[J].中国中医基础医学杂志,2016,22(8):1061~1064.
[9] 刘金连,王海芳,马淑惠,等.羟基红花黄色素A通过抑制动脉内皮细胞中TNFR1/NF-κB信号通路而发挥抗炎作用[J].细胞与分子免疫学杂志,2015,31(7):945~948.
[10] Gerwin RD. Diagnosis of myofascial pain syndrome[J]Phys Med Rehabil Clin N Am,2014,25(2):341~355. |
|
|
|
2018, Vol. 24 
